TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 10:00ET SEC's Gensler testifies at Senate Banking Committee; 1:00ET 10 year note auction TODAY’S HIGHLIGHTS: Quarter of Libyan city of Derna wiped out by burst dam, 1,000 bodies recoveredDOJ begins antitrust trial against GOOGLE, the biggest antitrust case in 20 years Bill
DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of
Peripheral artery disease affects around 1 in 20 Americans over the age of 50, occurring when blood flow is limited by blocked arteries. The patients were treated with the implantation of a Human Acellular Vessel (HAV), a bioengineered tissue, to from Humacyte to facilitate revascularization.
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Weeks after Russian tanks rolled into Ukraine in early 2022, a North Carolina biotech company that has done work for the Pentagon scrambled to help civilians and soldiers wounded by the war.